Venus Remedies has received marketing authorisations for its generic cancer drugs from Uzbekistan and Palestine. Having over 800 marketing authorizations worldwide, the company is making big strides by extending its footprint in Central Asia and Middle East with the marketing approval for Carboplatin in Uzbekistan and Docetaxel and Irinotecan in Palestine. These countries have limited access to quality medicines, and Venus Remedies is expected to launch these drugs in the two countries in the next financial year.
These marketing authorisations have further strengthened the company's commitment to providing cost-effective generic alternatives to expensive branded drugs and improving access to affordable Medicines to cancer patients in need. With these marketing approvals, the three generic cancer drugs signifying advances in cancer treatment will considerably benefit thousands of patients as well as the broader healthcare community.
Venus Remedies is one of the handful player in pharmaceutical sector to launch world global injectable manufacturers. It has world-class manufacturing facilities in Panchkula and Baddi (in India) and Werne (in Germany) and research and development center in Venus Medicine Research Centre (in India).
